14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure

被引：0
|
作者：
Thong-Ngam, D [1 ]
Mahachai, V [1 ]
机构：
[1] Chulalongkorn Univ Hosp, Bangkok, Thailand
来源：
HELICOBACTER | 2005年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：537 / 538
页数：2
相关论文
共 50 条
  • [41] Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best
    Yamaoka, Yoshio
    Graham, David Y.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1476 - S1478
  • [42] Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments
    Sapmaz, Ferdane
    Kalkan, Ismail Hakki
    Guliter, Sefa
    Atasoy, Pinar
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (03) : 224 - 229
  • [43] Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride
    Williams, MP
    Hamilton, MR
    Sercombe, JC
    Pounder, RE
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (04) : 705 - 710
  • [44] Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection
    Mönkemüller, KE
    Hirschowitz, BI
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (05) : 661 - 665
  • [45] Ranitidine bismuth citrate plus azithromycin for Helicobacter pylori eradication
    Bujanda, L
    Muñoz, C
    Sánchez, A
    Iriondo, C
    Cosme, A
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 30 (03) : 337 - 338
  • [46] The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis
    Ding, Yu-Ming
    Li, Yue-Yue
    Liu, Jing
    Wang, Juan
    Wan, Meng
    Lin, Min-Juan
    Lin, Bo-Shen
    Zhang, Wen-Lin
    Kong, Qing-Zhou
    Wang, Shao-Tong
    Mu, Yi-Jun
    Duan, Miao
    Han, Zhong-Xue
    Zuo, Xiu-Li
    Li, Yan-Qing
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (04) : 1033 - 1043
  • [47] The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis
    Yu-Ming Ding
    Yue-Yue Li
    Jing Liu
    Juan Wang
    Meng Wan
    Min-Juan Lin
    Bo-Shen Lin
    Wen-Lin Zhang
    Qing-Zhou Kong
    Shao-Tong Wang
    Yi-Jun Mu
    Miao Duan
    Zhong-Xue Han
    Xiu-Li Zuo
    Yan-Qing Li
    Clinical and Experimental Medicine, 2023, 23 : 1033 - 1043
  • [48] 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial
    Amiot, Aurelien
    Hacoon, Jeremy
    Heluwaert, Frederic
    Mion, Francois
    Lamarque, Dominique
    Moussata, Driffa
    Mimouni, Maroua
    Delchier, Jean-Charles
    Durand-Zaleski, Isabelle
    Audureau, Etienne
    Bastuji-Garin, Sylvie
    HELICOBACTER, 2024, 29 (02)
  • [49] Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection
    Graham, DY
    Hoffman, J
    Anderson, SY
    Qureshi, W
    Osato, MS
    El-Zimaity, HMT
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (02) : 169 - 172
  • [50] Levofloxacin-vs. ranitidine bismuth citrate-containing therapy after H-pylori treatment failure
    Gisbert, Javier P.
    Gisbert, Jose Luis
    Marcos, Santiago
    Moreno-Otero, Ricardo
    Pajares, Jose Maria
    HELICOBACTER, 2007, 12 (01) : 68 - 73
12345